Estrella Net Income From Continuing Ops from 2010 to 2026
| ESLA Stock | 1.12 0.04 3.70% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -6.6 M | Current Value -6.9 M | Quarterly Volatility 2.9 M |
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 2 K, Selling General Administrative of 1.2 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 289. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
Estrella | Net Income From Continuing Ops | Build AI portfolio with Estrella Stock |
Analyzing Estrella Immunopharma's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Estrella Immunopharma's current valuation and future prospects.
Latest Estrella Immunopharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Estrella Immunopharma over the last few years. It is Estrella Immunopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Estrella Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (2,632,575) | |
| Coefficient Of Variation | (110.87) | |
| Mean Deviation | 2,568,815 | |
| Median | (733,693) | |
| Standard Deviation | 2,918,745 | |
| Sample Variance | 8.5T | |
| Range | 6.6M | |
| R-Value | (0.81) | |
| Mean Square Error | 3.2T | |
| R-Squared | 0.65 | |
| Significance | 0.000093 | |
| Slope | (466,055) | |
| Total Sum of Squares | 136.3T |
Estrella Net Income From Continuing Ops History
About Estrella Immunopharma Financial Statements
Estrella Immunopharma stakeholders use historical fundamental indicators, such as Estrella Immunopharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Estrella Immunopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Estrella Immunopharma's assets and liabilities are reflected in the revenues and expenses on Estrella Immunopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -6.6 M | -6.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out the analysis of Estrella Immunopharma Correlation against competitors. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. Projected growth potential of Estrella fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Estrella Immunopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Estrella Immunopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Estrella Immunopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Estrella Immunopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.